 Prevalence of breast cancer (BC) ranged between 41-73 per 100K population across EU5. Among BC patients, prevalence of mBC was similar: 8% (UK, Italy) to 10% (Germany, France, Spain). Overall, 62% of mBC patients were diagnosed with HER2-negative disease (56% Germany; 70% France). Among these patients, 35%-40% had active disease and were treated with chemotherapy.
 Historical age-, gender-, and stage-specific incidence rates are obtained from countryspecific registry sources. These rates of disease are then applied to country-specific population data to calculate age, gender, and stage-specific number of newly diagnosed patients. Projections of the historical incidence rates to future years are done using Bass diffusion curve modeling.
 Stage-specific recurrence/progression rates as well as survival rates are obtained from either these same cancer registries or in-depth literature search and review, depending on the country. The annual stage-specific cumulative rates of recurrence/ progression and the annual stage-specific cumulative rates of survival are used to calculate the number of patients at a specific stage of disease among all surviving patients up to 9 years post diagnosis (10-year restaged prevalence).
 Treatment data from the Treatment Architecture module of CancerMPact® is based on physician surveys conducted annually. The current breast cancer survey was fielded in July 2013. This was an internet survey of 83 physicians who treated a total of 9,255 breast cancer patients per month.
 The modality and drug treatment rates from Treatment Architecture are applied to a treatment eligible subset of the above-mentioned restaged prevalence patient group to arrive at the number of patients treated with specific modalities or drug regimens in a given year.
 Sources are noted in the accompanying OBJECTIVE: Explore differences/similarities in epidemiology and drug treatment of metastatic breast cancer (mBC) in EU5. METHODS: All data was derived from the Kantar Health CancerMPact® database, sources for which include countryspecific cancer registries, published scientific studies, and proprietary physician surveys comprising of 83 doctors seeing an average of 9,255 patients per month. Age-and gender-specific incidence rates, annual stage-specific progression rates, and annual stage-specific survival rates are used to calculate total number of surviving patients at a specific stage up to 10 years after diagnosis. RESULTS: Prevalence of breast cancer (BC) ranged between 41-73 per 100K population across EU5. Among BC patients, prevalence of mBC was similar: 8% (UK, Italy) to 10% (Germany, France, Spain). Overall, 62% of mBC patients were diagnosed with HER2-negative disease (56% Germany; 70% France). Among these patients, 35-40% had active disease and were treated with chemotherapy. Patients with triple-negative disease had fewer lines of treatment than did patients without triple-negative disease. Patients who are HER2-negative generally receive between two and three lines of chemotherapy on average. Second-line chemotherapy regimens varied. Capecitabine was the most common therapy (mono and combination) in all countries ranging from 36% (UK) to 40% (Germany). Second and third most common therapies were vinorelbine (23%-26%) and paclitaxel (20%-23%) in Germany, Italy, and Spain vs. docetaxel (18%-34%) and paclitaxel (11%-19%) in UK and France. In third-line, the most commonly used agents were capecitabine (16%-44%) and vinorelbine (18%-26%). Eribulin was used in second-line (3%-6%) and third-line (11%-19%) in all countries except for Spain. CONCLUSION: Capecitabine is the most utilized chemotherapeutic agent in the second-and third-lines of chemotherapy in Western Europe for HER2-negative patients. A variety of other regimens, primarily monotherapies, may also be used in later lines, including vinorelbine, gemcitabine, eribulin, and docetaxel.
ABSTRACT
 Patients with triple-negative disease (ER-/PR-/HER2-) had fewer lines of treatment than did other breast cancer patients. Patients who are HER2-negative generally receive between two and three lines of chemotherapy on average. Second-line chemotherapy regimens varied. Capecitabine was the most common therapy (mono and combination) in all countries ranging from 36% (UK) to 40% (Germany). The second and third most common therapies were vinorelbine (23%-26%) and paclitaxel (20%-23%) in Germany, Italy, and Spain vs. docetaxel (18%-34%) and paclitaxel (11%-19%) in UK and France. In third-line, the most commonly used agents were capecitabine (16%-44%) and vinorelbine (18%-26%). Eribulin was used in second-line (3%-6%) and third-line (11%-19%) in all countries except for Spain. In HER2-negative mBC patients previously treated with anthracyclines and taxanes, the main later line therapies across EU5 are capecitabine (40.7%), vinorelbine (14.8%), eribulin (6.3%), and gemcitabine (11.7%). 
